China aims to extend pilot initiatives for biotechnology and wholly foreign-owned hospitals, the report indicates

China aims to extend pilot initiatives for biotechnology and wholly foreign-owned hospitals, the report indicates

China Expands Pilot Programs for Foreign Investment in Biotechnology and Healthcare

China has announced the extension of pilot initiatives to liberalize foreign investment in biotechnology and healthcare sectors, signaling a strategic shift to attract international capital and advance its economic openness. Effective from September 2024, foreign-invested enterprises (FIEs) are permitted to engage in the development and application of human stem cell and gene therapy technologies within four free trade zones (FTZs): Beijing, Shanghai, Guangdong, and Hainan. These activities, aimed at product registration, listing, and production, will allow approved therapies to be marketed nationwide.

The move aligns with the revised Special Administrative Measures for Foreign Investment Access (Negative List) (2024 Edition), which removed longstanding restrictions on foreign participation in biotechnology sectors, albeit with compliance requirements. FIEs must adhere to regulations governing human genetic resources, clinical trials, and ethical review, ensuring alignment with China's biosecurity priorities according to policy documents. This policy shift addresses industry calls for greater flexibility, as prior prohibitions on foreign investment in stem cell and gene therapy research had hindered sector growth as reported.

In parallel, China has permitted the establishment of wholly foreign-owned hospitals in nine cities—Beijing, Tianjin, Shanghai, Nanjing, Suzhou, Fuzhou, Guangzhou, Shenzhen, and Hainan—excluding traditional Chinese medicine and public hospital acquisitions. The National Health Commission (NHC) detailed implementation plans in November 2024, emphasizing streamlined procedures for foreign investors. Previously, foreign medical investments were restricted to joint ventures, limiting autonomy for international operators. The new policy aims to introduce advanced medical technologies, management practices, and services, addressing rising domestic healthcare demand amid an aging population according to industry analysis.

While these reforms present opportunities, investors must navigate regulatory complexities, including data security requirements and pre-approval processes for medical services. Authorities have also emphasized compliance with national treatment principles and biosecurity frameworks as stated by regulatory bodies.

The initiatives reflect broader State Council directives to accelerate sectoral openness, particularly in healthcare, education, and telecommunications. As pilot programs evolve, further expansion to cities like Tianjin is anticipated, potentially reshaping China's biotech and healthcare investment landscape according to policy outlooks.